{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T21:30:32Z","timestamp":1764883832082,"version":"3.46.0"},"reference-count":34,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"unspecified","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,10,15]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The widespread application of interleukin (IL) inhibitors for various conditions, including gastrointestinal, rheumatologic, dermatologic and pulmonary diseases, has raised concerns regarding the potential for hepatitis B virus reactivation (HBVr). However, the precise risk of HBVr remains unclear due to inconsistencies in existing research. This systematic review aims to quantify the risk of HBVr in patients receiving IL inhibitor therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This systematic review will follow Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A comprehensive search will be conducted in MEDLINE, PubMed, Google Scholar, CENTRAL, Scopus, Embase, Web of Science and ClinicalTrials.gov up to October 2025. Two reviewers will independently screen studies and extract data, resolving discrepancies by consensus. Eligible studies will include HBV-infected patients receiving IL inhibitors. HBVr rates will be estimated using a generalised linear mixed model with a binomial distribution, applying random-effects models to account for interstudy variability. Heterogeneity will be assessed using I\u00b2, Cochran\u2019s Q and \u03c4\u00b2. Leave-one-out sensitivity analyses will evaluate robustness. Subgroup analyses will consider HBV serostatus, IL inhibitor type and study characteristics. Studies including patients on antiviral prophylaxis will be excluded from the primary analysis. A secondary analysis will assess prophylaxis efficacy in preventing HBVr according to hepatitis B surface antigen status. Publication bias will be evaluated using Doi plots and the Luis Furuya-Kanamori index.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study does not require ethics approval as it involves no patient-specific data. Findings will be disseminated at gastroenterology conferences and through peer-reviewed publications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>The protocol is registered in PROSPERO (CRD42024614179).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-098671","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T08:57:09Z","timestamp":1762851429000},"page":"e098671","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of hepatitis B virus reactivation associated with interleukin inhibitor therapies: protocol for a systematic review and meta-analysis"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5027-2096","authenticated-orcid":false,"given":"Marouf Mouhammad","family":"Alhalabi","sequence":"first","affiliation":[{"name":"Internal Medicine\/Department of Gastroenterology & Hepatology, Damascus Hospital, Damascus, Syrian Arab Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8078-2830","authenticated-orcid":false,"given":"Hussam Aldeen","family":"Alshiekh","sequence":"additional","affiliation":[{"name":"Internal Medicine\/Department of Gastroenterology & Hepatology, Ibn Al-Nafees Hospital, Damascus, Syrian Arab Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,11,9]]},"reference":[{"key":"2025120413262074000_15.11.e098671.1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1331217","article-title":"IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy","volume":"15","author":"Krueger","year":"2024","journal-title":"Front Immunol"},{"key":"2025120413262074000_15.11.e098671.2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2024.05.036","article-title":"Targeting the Interleukin 23 Pathway in Inflammatory Bowel Disease","volume":"168","author":"Bourgonje","year":"2025","journal-title":"Gastroenterology"},{"key":"2025120413262074000_15.11.e098671.3","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/S0140-6736(24)01750-1","article-title":"IL-23 inhibition for chronic inflammatory disease","volume":"404","author":"Jairath","year":"2024","journal-title":"Lancet"},{"key":"2025120413262074000_15.11.e098671.4","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X17735756"},{"key":"2025120413262074000_15.11.e098671.5","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00578-0"},{"key":"2025120413262074000_15.11.e098671.6","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-015-0569-8"},{"key":"2025120413262074000_15.11.e098671.7","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1097\/RHU.0000000000001293","article-title":"Role of Interleukin 6 Inhibitors in the Management of Rheumatoid Arthritis","volume":"27","author":"Yip","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"2025120413262074000_15.11.e098671.8","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-021-10239-x"},{"key":"2025120413262074000_15.11.e098671.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.07.003"},{"key":"2025120413262074000_15.11.e098671.10","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17155"},{"key":"2025120413262074000_15.11.e098671.11","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/apt.17682","article-title":"Letter: Incidence of hepatitis B virus reactivation in patients with psoriasis treated with cytokine inhibitors","volume":"58","author":"Kuo","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2025120413262074000_15.11.e098671.12","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.10.039"},{"key":"2025120413262074000_15.11.e098671.13","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40264-024-01399-4","article-title":"Consensus Guidelines: Best Practices for the Prevention, Detection and Management of Hepatitis B Virus Reactivation in Clinical Trials with Immunosuppressive\/Immunomodulatory Therapy","volume":"47","author":"Cohen","year":"2024","journal-title":"Drug Saf"},{"key":"2025120413262074000_15.11.e098671.14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MEG.0000000000002863","article-title":"The incidence of hepatitis B reactivation in patients receiving ustekinumab: a systematic review and proportional meta-analysis","volume":"37","author":"Alhalabi","year":"2025","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025120413262074000_15.11.e098671.15","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/rheumatology\/keae445","article-title":"Hepatitis B reactivation in PsA patients: an SLR and meta-analysis for IL-17, IL-23 and JAK inhibitors","volume":"64","author":"Androutsakos","year":"2025","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2025120413262074000_15.11.e098671.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2016.06.006"},{"key":"2025120413262074000_15.11.e098671.17","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","article-title":"Global, regional, and national burden of hepatitis B, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"7","author":"Sheena","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025120413262074000_15.11.e098671.18","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-025-11063-6","article-title":"Prevalence of opportunistic infections in Syrian inflammatory bowel disease patients on biologic therapy: a multi-center retrospective cross-sectional study","volume":"25","author":"Alhalabi","year":"2025","journal-title":"BMC Infect Dis"},{"key":"2025120413262074000_15.11.e098671.19","doi-asserted-by":"crossref","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"2025120413262074000_15.11.e098671.20","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2025120413262074000_15.11.e098671.21","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"2025120413262074000_15.11.e098671.22","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-025-02923-y","article-title":"Hepatitis B reactivation with TNF-\u03b1 inhibitors: assessing antiviral prophylaxis efficacy - protocol for systematic review and meta-analysis","volume":"14","author":"Marouf","year":"2025","journal-title":"Syst Rev"},{"key":"2025120413262074000_15.11.e098671.23","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"2025120413262074000_15.11.e098671.24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/jrsm.1378","article-title":"Which academic search systems are suitable for systematic reviews or meta-analyses? Evaluating retrieval qualities of Google Scholar, PubMed, and 26 other resources","volume":"11","author":"Gusenbauer","year":"2020","journal-title":"Res Synth Methods"},{"key":"2025120413262074000_15.11.e098671.25","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-017-0644-y","article-title":"Optimal database combinations for literature searches in systematic reviews: a prospective exploratory study","volume":"6","author":"Bramer","year":"2017","journal-title":"Syst Rev"},{"key":"2025120413262074000_15.11.e098671.26","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2025120413262074000_15.11.e098671.27","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2025120413262074000_15.11.e098671.28","unstructured":"West SL , Gartlehner G , Mansfield AJ , et al . Table 7, Summary of common statistical approaches to test for heterogeneity.2010. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK53317\/table\/ch3.t2\/"},{"key":"2025120413262074000_15.11.e098671.29","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/XEB.0000000000000141","article-title":"A new improved graphical and quantitative method for detecting bias in meta-analysis","volume":"16","author":"Furuya-Kanamori","year":"2018","journal-title":"Int J Evid Based Healthc"},{"key":"2025120413262074000_15.11.e098671.30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"2025120413262074000_15.11.e098671.31","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9675-4"},{"key":"2025120413262074000_15.11.e098671.32","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"2025120413262074000_15.11.e098671.33","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"83","author":"Cornberg","year":"2025","journal-title":"J Hepatol"},{"key":"2025120413262074000_15.11.e098671.34","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab052"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-098671","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T21:27:35Z","timestamp":1764883655000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-098671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":34,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,9]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/bmjopen-2024-098671"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-098671","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}